We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$980M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+2.41%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$242M
AUM Growth
-$107M
(-31%)
Cap. Flow
-$82.3M
Cap. Flow
% of AUM
-33.98%
Top 10 Holdings %
Top 10 Hldgs %
35.16%
Holding
111
New
21
Increased
25
Reduced
24
Closed
39
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRUS
Merus
MRUS
|
+$6.87M |
| 2 |
ETNB
89bio
ETNB
|
+$5.71M |
| 3 |
KALV
KalVista Pharmaceuticals
KALV
|
+$5.4M |
| 4 |
Cogent Biosciences
COGT
|
+$5.12M |
| 5 |
Karyopharm Therapeutics
KPTI
|
+$5.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$10.9M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$10.4M |
| 3 |
Immunovant
IMVT
|
+$9.22M |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$5.8M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
+$5.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.87% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Ascendis Pharma A/S
ASND
$16B
| – | – |
-23,151
| Closed | -$2.83M |
|
|
JBIO
77
Jade Biosciences
JBIO
$1.2B
| – | – |
-1,054
| Closed | -$1.08M |
|
78
CALL
Anavex Life Sciences
AVXL
$255M
| – | – |
-102,600
| Closed | -$950K |
|
|
79
PUT
Anavex Life Sciences
AVXL
$255M
| – | – |
-1,007,700
| Closed | -$9.33M |
|
80
Axsome Therapeutics
AXSM
$11.2B
| – | – |
-10,000
| Closed | -$771K |
|
81
BioAtla
BCAB
$5.46M
| – | – |
-10,938
| Closed | -$4.51M |
|
82
Braze
BRZE
$2.81B
| – | – |
-10,000
| Closed | -$273K |
|
83
Codexis
CDXS
$151M
| – | – |
-144,737
| Closed | -$674K |
|
84
Compass Therapeutics
CMPX
$344M
| – | – |
-268,307
| Closed | -$1.35M |
|
85
Crinetics Pharmaceuticals
CRNX
$8.84B
| – | – |
-152,747
| Closed | -$2.8M |
|
86
Cytokinetics
CYTK
$10.5B
| – | – |
-17,500
| Closed | -$802K |
|
87
Design Therapeutics
DSGN
$761M
| – | – |
-57,025
| Closed | -$585K |
|
88
Evogene
EVGN
$5.7M
| – | – |
-15,036
| Closed | -$105K |
|
89
Gossamer Bio
GOSS
$82.9M
| – | – |
-100,000
| Closed | -$217K |
|
90
GSK
GSK
$104B
| – | – |
-136,178
| Closed | -$4.79M |
|
91
Immunic
IMUX
$190M
| – | – |
-35,066
| Closed | -$491K |
|
|
92
Immunovant
IMVT
$7.93B
| – | – |
-519,614
| Closed | -$9.22M |
|
|
93
PUT
Madrigal Pharmaceuticals
MDGL
$10.8B
| – | – |
-30,000
| Closed | -$8.71M |
|
94
MeiraGTx Holdings
MGTX
$1.09B
| – | – |
-56,672
| Closed | -$370K |
|
95
Vaxcyte
PCVX
$7.81B
| – | – |
-83,135
| Closed | -$3.99M |
|
96
Phreesia
PHR
$663M
| – | – |
-85,390
| Closed | -$2.76M |
|
97
Praxis Precision Medicines
PRAX
$8.58B
| – | – |
-6,561
| Closed | -$234K |
|
98
Prothena Corp
PRTA
$425M
| – | – |
-71,706
| Closed | -$4.32M |
|
99
uniQure
QURE
$3.03B
| – | – |
-10,000
| Closed | -$227K |
|
|
RNAM
100
DELISTED
Avidity Biosciences
RNAM
| – | – |
-128,000
| Closed | -$2.84M |
|
Similar funds
BIP
MVM
MFWP
FCM
KL
GFP
ADIC
PCM
Silverarc Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Silverarc Capital Management held 111 positions worth $242M, down 31% from $350M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Silverarc Capital Management withdrew a net $82.3M in Q1 2023, closing 39 positions and reducing 24 holdings. Its most notable exit was Immunovant, an estimated $9.22M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 80% a quarter earlier, followed by Technology.
Against the trend, Silverarc Capital Management opened a new position in 89bio worth $6.67M.
- Silverarc Capital Management's largest Q1 2023 buy was 89bio: 438,215 shares worth $6.67M.
- Silverarc Capital Management added most to Merus in Q1 2023, an estimated $6.87M increase.
- Silverarc Capital Management's biggest Q1 2023 reduction was Madrigal Pharmaceuticals, cutting an estimated $10.9M.
- Silverarc Capital Management fully exited Immunovant in Q1 2023, selling an estimated $9.22M.
- Silverarc Capital Management's ten largest holdings make up 35% of its $242M portfolio in Q1 2023.
- Silverarc Capital Management opened 21 new positions and closed 39 in Q1 2023.
- Silverarc Capital Management's portfolio value fell 31% quarter-over-quarter to $242M.
Based on Silverarc Capital Management's 13F filing for Q1 2023, filed 15 May 2023.